Modulators of dopamine neurotransmission

Details Modulators of dopamine neurotransmission Modulators of dopamine neurotransmission

2004-12-21

2008-08-26

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S394000, C544S392000, C544S395000, C424S250100

Reexamination Certificate

active

07417043

ABSTRACT:
A 3-substituted 4-(phenyl-N-alkyl)-piperazine compound of the following formula:wherein R1is selected from the group consisting of OSO2CF3, OSO2CH3, SO2R3, COCF3, COCH3and COCH2CH3, wherein R3is as defined hereafter; R2is selected from the group consisting of C1-C4alkyls, allyl, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl and 4,4,4-trifluorobutyl; R3is selected from the group consisting of C1-C3alkyls, CF3, and N(CH3)2; with the proviso that when R1is SO2R3and R3is a C1-C3alkyl, then R2is not CH2CH2OCH3; or a pharmaceutically acceptable salt thereof are provided. Also, pharmaceutical compositions comprising the above compound and methods wherein the above compound is used for the treatment of various disorders are provided.

REFERENCES:
patent: 3326916 (1967-06-01), Creighton
patent: 3539573 (1970-11-01), Schmutz et al.
patent: 4202898 (1980-05-01), Depoortere
patent: 4267328 (1981-05-01), Najer et al.
patent: 4333942 (1982-06-01), Eistetter et al.
patent: 4415736 (1983-11-01), Ciganek et al.
patent: 4504660 (1985-03-01), Klaubert et al.
patent: 4892875 (1990-01-01), Meguro et al.
patent: 5462947 (1995-10-01), Svensson et al.
patent: 5502050 (1996-03-01), Gross
patent: 6175015 (2001-01-01), Yuan et al.
patent: 6903120 (2005-06-01), Sonesson et al.
patent: 6924374 (2005-08-01), Sonesson et al.
patent: 0 060 179 (1982-02-01), None
patent: 2 083 476 (1982-03-01), None
patent: 0094159 (1983-11-01), None
patent: 0 369 887 (1990-05-01), None
patent: 0 533 267 (1992-09-01), None
patent: 0 533 266 (1993-03-01), None
patent: 0 533 268 (1993-03-01), None
patent: 0 675 118 (2002-10-01), None
patent: 1459013 (1966-11-01), None
patent: 850662 (1960-10-01), None
patent: 1 560 271 (1980-02-01), None
patent: 2 027 703 (1980-02-01), None
patent: 2 078 746 (1982-01-01), None
patent: 6510107 (1966-02-01), None
patent: WO 89/05799 (1989-06-01), None
patent: WO 91/09594 (1991-07-01), None
patent: WO 92/18475 (1992-10-01), None
patent: WO 93/00313 (1993-01-01), None
patent: WO/9703986 (1997-02-01), None
patent: WO 98/11068 (1998-03-01), None
patent: WO 00/03713 (2000-01-01), None
patent: WO 00/78728 (2000-12-01), None
patent: WO01/46145 (2001-06-01), None
patent: WO 01/46146 (2001-06-01), None
patent: WO 02/05819 (2002-01-01), None
patent: WO 02/059108 (2002-08-01), None
patent: WO 2004/099150 (2004-11-01), None
patent: WO 2005/019215 (2005-03-01), None
patent: WO 2005/121092 (2005-12-01), None
Chemical Abstract CA 132:35590. “Synthesis of piperidine analogos of 1-(3-chlorophenyl)piperazine, a well known serotonin ligand.” Radl et al., Journal of Heterocyclic Chemistry (1999), 36(4), pp. 1017-1022.
Chemical Abstract CA 116:250000. “Quantitative structure-metabolism relationship analyses of MAO-medicated toxication of 1-methyl-4-phenyl-1,2,3,5-tetrahydropyridine and analogs.” Cosimo et al., Chemical Research in Toxicology (1992), 5(3), pp. 366-375.
Chemical Abstract DN 65:38471, also cited as NL 6510107.
U.S. Appl. No. 10/168,297, filed Nov. 20, 2002.
Joseph T. Coyle et al, Science vol. 219, 1184-1190 (1983).
Grunblatt et al. (PubMed Abstract 10335493).
Grunblatte et al. (PubMed Abstract 10863545).
Carlsson et al., “Interactions Between Glutamatergic and Monoaminergic Systems within the Basal Ganglia—Implications for Schizophrenia and Parkinson's Disease”, TINS, (1990), pp. 272-276, vol. 13, No. 7, Elsevier Science Publishers Ltd., United Kingdom.
Feldman et al. (Editors), “Principles of Neuropsychopharmacology”, Chapter 17—Mind Altering Drugs, (1997), pp. 731, 762, 763, Sinauer Associates, Inc., Publishers, Sunderland, Massachusetts, USA.
Bloom et al. (Editors), “Psychopharmacology—The Fourth Generation of Progress”, Chapter 21, pp. 227, 237, Chapter 22, pp. 245, 254, Chapter 25, pp. 283, 292, Chapter 26, pp. 295-301, Chapter 6, pp. 759-760, 1725, 744-746, Chapter 68, pp. 787, 793-795, Chapter 80, pp. 921-925, 927-928, Chapter 101, pp. 1205, 1207-1209, Chapter 111, pp. 1311, 1317, 1318, 1320, Chapter 126, pp. 1479-1482, Chapter 137, pp. 1591, 1600, Chapter 138, pp. 1609-1610, 1612, (1995), Raven Press, New York, New York, USA.
Clas Sonesson et al., “Substituted(S)-Phenylpiperidines and Rigid Congeners as Preferential Dopamine Autoreceptor Antagonists: Synthesis and Structure-Activity Relationships”, Journal of Medicinal Chemistry, 1994, vol. 37, No. 17, pp. 2735 to 2753.
Zhang, et al., “Studies on antimalarials. III. Synthesis and antimalarial effects of some derivatives of 2,4-diamino-6-substituted piperazinylquinazolines”,Acta Pharmaceutica Sinica, Jun. 1981, pp. 415-424, vol. 16, No. 6, Shanghai Inst. Pharm. Ind. Res., Shanghai, Peop, Rep. of China.
Takai, et al., “Reaction of Spiro[4H-3,1-benzoxazine-4,4'-piperdin]-2(1H)-one Derivatives and Related Compounds with Phosphorus Oxychloride”,Chemical & Pharmaceutical Bulletin., May 1986, pp. 1901-1906, vol. 34, No. 5, Pharmaceutical Society of Japan, Tokyo, JP.
Egawa, et al., “A New Synthesis of 7H-Pyrido[1,2,3-de][1,4]benzoxazine Derivatives Including an Antibacterial Agent, Ofloxacin1”,Chemical & Pharmaceutical Bulletin, Oct. 1986, pp. 4098-4102, vol. 34, No. 10, Pharmaceutical Society of Japan, Tokyo, JP.
Beugelmans, et al., “Synthèsse d'hétérocycles à 5 et 6 chaînons par une stratégie combinant des réactions SNAr et SRN1”,Bull Soc Chim Fr., 1995, pp. 306-313, vol. 132, Elsevier, Paris, FR.
Morita, et al., “Practical Application of the Palladium-catalyzed Amination in Phenylpiperazine Synthesis: An Efficient Synthesis of a Metabolite of the Antipsychotic Agent Aripiprazole”,Tetrahedron, May 7, 1998, pp. 4811-4818, vol. 54, No. 19, Pergamon, Elsevier Science Ltd., Oxford, England & NY, USA.
Smaill, et al., “Mono- and difunctional nitrogen mustadr analogues of the DNA minor groove binder pibenzimol. Synthesis, cytotxicity and interaction with DNA”,Anti-Cancer Drug Design, 1998, pp. 221-242, vol. 13, Oxford University Press.
Klaubert, et al., “N-(Aminophenyl)oxamic Acids and Esters a Potent, Orally Active Antiallergy Agent”,J. Med. Chem., 1981, p. 742-748, vol. 24, American Chemical Society, Washington, DC.
Self, et al., “cineandteleSubstitutions in the Reaction of 2,3-Dinitroaniline with Secondary Amines”,J.C.S. Chem. Comm., 1980, pp. 281-282, Royal Society of Chemistry, UK.
Elslager, et al., “Folate Antagonists. 3. 2,4-Diamino-6-(heterocyclic)quinazolines, a Novel Class of Antimetabolites with Potent Antimalarial and Antibacterial Activity”,Journal of Medicinal Chemistry, 1972, pp. 827-836, vol. 15, No. 8, American Chemical Society, Washington, DC.
Berberian, et al., “Comparison of Schistosomicidal Activity of Xanthenones adn 4-Methyl-3-chloroanilines and Their Hydroxymethyl Analogs in Swiss Mice and Syrian Hamsters Infected withSchistosoma mansoni”,Jpurnal of Medicinal Chemistry, Jul. 1969, pp. 607-610, vol. 12, No. 4, American Chemical Society, Washington, DC.
Henry, “A Facile Synthesis of Piperazines from Primary Amines (1)”,Journal of Heterocyclic Chemistry, 1966, pp. 503-511, vol. 3, No. 4, Heterocorporation, USA.
Oshiro, et al., “Novel Antisychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives”,J. Med. Chem., 1998, pp. 658-667, vol. 41, American Chemical Society, Washington, DC.
Manoury, et al., “Synthesis and Analgesic Activities of Some (4-Substituted phenyl-1-piperazinyl)alkyl 2-Aminobenzoates and 2-Aminocotinates”,Journal of Medicinal Chemistry, 1979, pp. 554-559, vol. 22, No. 5, American Chemical Society, Washington, DC.
“Biologic Test Methods”,Burger's Medicinal Chemistry, Fourth Edition, Part III, Edited by Manfred E. Wolff, pp. 872-873, John Wiley & Sons, NY, USa.
Strange, “Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions

Affiliated with

Also associated with

Rating

Modulators of dopamine neurotransmission does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulators of dopamine neurotransmission, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of dopamine neurotransmission will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4019806